Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Total Current Assets
All assets expected to be converted to cash or used up within one year.
Bicycle Therapeutics plcNASDAQ: BCYC
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 27.7% from a year ago
Total current assets stood at $619.14M at the end of Q1 FY2026, down 27.7% from a year earlier and down 1.4% from the prior quarter. Over 3 fiscal years it compounded at +19.4% a year.
Context
- Total current assets amounted to 94.9% of total assets at the end of Q1 FY2026, down 2.0 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -27.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 628.11M USD
- Year-over-year change
- -32.4%
- 4-year CAGR
- +8.2%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 628.11M | -32.4% |
| FY2024 | 2024-12-31 | 928.61M | +65.3% |
| FY2023 | 2023-12-31 | 561.87M | +52.1% |
| FY2022 | 2022-12-31 | 369.38M | -19.4% |
| FY2021 | 2021-12-31 | 458.56M | — |
Total Current Assets vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's Mar 2026 total current assets of $619.14M is the highest of the 10 companies compared; the peer median is $276.77M.
- Its year-over-year change of -27.7% is the 8th highest of 9, against a peer median of +14.6%.
- Total current assets amounts to 94.9% of total assets for BCYC, versus a peer median of 95.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $619.14M | -27.7% | +19.4% | 94.9% | |
| Mar 2026 | $405.36M | +21.9% | +23.3% | 79.0% | |
| Mar 2026 | $339.2M | -22.2% | -24.0% | 96.9% | |
| Mar 2026 | $338.67M | +45.6% | +19.9% | 97.7% | |
| Dec 2025 | $320.15M | — | — | 95.5% | |
| Mar 2026 | $276.77M | +7.3% | -11.0% | 94.9% | |
| Mar 2026 | $195.69M | +57.6% | +2.5% | 95.4% | |
| Mar 2026 | $186.03M | -24.3% | -10.2% | 69.2% | |
| Mar 2026 | $180.36M | +87.5% | -21.3% | 63.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M | -39.8% | -21.1% | 99.7% |
| Peer median (excluding BCYC) | $276.77M | +14.6% | -10.6% | 95.4% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.97M | 9.02M | 11.41M | 13.43M | (35.59M) |
| Total Current Assets | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M |
| Property, Plant & Equipment (Net) | 17.79M | 32.77M | 27.68M | 17.19M | 21.91M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 547K | 547K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.45M | 8.46M | 5.24M | 10.53M | 12.75M |
| Total Non-current Assets | 21.24M | 41.23M | 33.48M | 28.26M | 34.71M |
| Total Assets | 479.79M | 410.61M | 595.34M | 956.87M | 717.6M |
| Account Payables | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M |
| Short-term Debt | 0 | 0 | 4.88M | 0 | 2.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 19.27M | 20.42M | 24.98M | 10.19M | 2.96M |
| Other Current Liabilities | 7M | 13.4M | 13.24M | 16.57M | 17.14M |
| Total Current Liabilities | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M |
| Long-term Debt | 29.87M | 30.32M | 30.7M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 52.07M | 41.46M | 110.22M | 91.47M | 35.51M |
| Other Non-current Liabilities | 3.28M | 3.83M | 4.58M | 1.12M | 363K |
| Total Non-current Liabilities | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M |
| Total Liabilities | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M |
| Common Stock | 384K | 387K | 550K | 890K | 894K |
| Retained Earnings | (218.38M) | (331.1M) | (511.76M) | (680.79M) | (899.75M) |
| Accumulated OCI | (3.39M) | 387K | (1.3M) | 119K | (3.51M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M |
| Total Debt | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M |
| Net Debt | (394.34M) | (294.83M) | (481.47M) | (870.03M) | (610.59M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.